通心络胶囊对短暂性脑缺血发作患者血浆溶血磷脂酸含量变化的影响  

Influence of Tongxinluo capsule on plasma levels of lysophosphatidic acid in patients with transient ischemic attack

作　　者：刘南海[1] 黄晓峰[1] 彭文杰[1] 刘春棋[1] 江丽霞[1] 

机构地区：[1]赣南医学院第一附属医院神经内科,江西赣州341000

出　　处：《临床荟萃》2008年第23期1676-1678,共3页Clinical Focus

摘　　要：目的探讨溶血磷脂酸(LPA)在短暂性脑缺血发作(TIA)发生过程中的作用以及通心络胶囊治疗对LPA含量、TIA发生的影响。方法选取经临床和CT或MRI确诊的TIA患者92例,随机分为通心络胶囊组、阿司匹林组、合用通心络胶囊及阿司匹林组(合用治疗组),选择同期健康体检者31例为健康对照组。通心络胶囊组服用通心络胶囊每天3次,每次4粒,连续服用30天。阿司匹林组服用阿司匹林片每天1次,每次100 mg,连续服用30天。合用治疗组服用通心络胶囊每天3次,每次4粒,阿司匹林片每天1次,每次100 mg,连续服用30天。全部患者于发病24小时内及治疗30天结束时测定血浆LPA含量,并与健康对照组比较。观察通心络胶囊对TIA患者血浆LPA含量变化的影响,并随访6个月内TIA发生率和出血性并发症的发生率。结果3组患者发病24小时内血浆LPA含量分别为通心络胶囊组(4.91±0.92)μmol/L,阿司匹林组(4.55±0.98)μmol/L,合用治疗组(4.67±0.94)μmol/L,显著高于对照组(1.64±1.02)μmol/L(均P<0.01);治疗后血浆LPA含量分别为通心络胶囊组(2.56±1.03)μmol/L,阿司匹林组(2.49±0.99)μmol/L,合用治疗组(1.52±0.85)μmol/L,与治疗前比较均明显降低(P<0.01),以合用治疗组下降最为显著。合用治疗组TIA发生率(23.3%)低于通心络胶囊组(41.9%)和阿司匹林组(54.8%)(均P<0.05);3组患者出血并发症发生率极低。结论TIA患者血浆LPA含量增高明显,通心络胶囊与阿司匹林均可显著降低血浆LPA含量并可减少TIA发生,二者合用效果更佳。Objective To investigate the action of lysophosphatidic acid （LPA） in the process of transient ischemic attack（TIA） and to observe whether treatment with Tongxinluo capsule decreases LPA levels of patients with TIA and the episode of TIA. Methods Ninety-two patients with TIA were randomly divided into three treatment groups：treatment group with Tongxinluo capsule （ n = 31）, treatment group with aspirin （ n = 31） and combined treatment groups （n = 30）. 31 healthy adults were selected as normal controls. Patients in treatment group with Tongxinluo capsules were treated with Tongxinluo capsule 4 pills for 3 times a day. Patients in treatment group with aspirin were treated with aspirin 100 mg for once a day. Patients in combined treatment group were treated with Tongxinluo capsule 4 pills for 3 times a day,and with aspirin 100 nag for once a day. All of them were treated for 30 days consecutively. Blood samples were taken for measuring the level of LPA before and after the treatment respectively. The effects of Tongxinluo capsule and aspirin on plasma LPA level were observed,compared with control group,and the incidences of TIA and hemorrhagic complication were recorded within 6 months. Results The level of LPA before treatment in treatment group with Tongxinluo capsule, treatment group with aspirin and combined treatment group was respectively （4.91 ± 0.92） μmol/L, （4.55 ± 0.98） μmol/L, （4.67± 0.94） μmol/L, which was significantly higher than that in control group （1.64±1.02）μmol/L（all P 〈0.01）. After the treatment for 30 days, the average level of LPA in treatment group with Tongxinluo capsule, treatment group with aspirin and combined treatment group was respectively（2.56± 1.03） μmol/L, （2.49 ± 0.99） μmol/L, （1.52 ± 0.85）μmol/L, and decreased significantly （ P 〈0.01） ,and that in combined treatment group was the lowest. The incidence of TIA within 6 months in combined treatment group （23.3 %） was the lowest compared with Tongxinluo ca

关 键 词：脑缺血发作 短暂性 溶血磷脂素类 植物制剂 阿司匹林 

分 类 号：R743.3[医药卫生—神经病学与精神病学]